Daniel K. Harris

Daniel is responsible for the development of Lumicell’s imaging drug including all aspects of manufacturing and CMC. He also leads regulatory strategy and is responsible for preparation of Lumicell’s NDA and other drug related regulatory filings. Prior to joining Lumicell, Daniel led the chemistry R&D group at QD Vision, a nanomaterials company developing fluorescent materials for the consumer display market, and supported the company through its acquisition by Samsung. Daniel received his Ph.D. from Massachusetts Institute of Technology, studying in the laboratory of Dr. Moungi Bawendi and developing fluorescent nanomaterials for in vivo imaging. He received a BS in Chemical Engineering from the University of Southern California. He is an author on 14 academic papers and an inventor on three patents.